Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiary Referral Centre in Tuscany.
暂无分享,去创建一个
C. Di Mario | I. Olivotto | M. Allinovi | F. Perfetto | M. Zampieri | C. Fumagalli | F. Cappelli | S. Casagrande | C. Zocchi | G. Nardi | M. Gabriele | G. Del Monaco | Guido Del Monaco | Marco Allinovi
[1] C. Di Mario,et al. Incidence of light chain amyloidosis in Florence metropolitan area, Italy: a population-based study , 2021, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[2] A. Wechalekar,et al. Epidemiologic and Survival Trends in Amyloidosis, 1987-2019. , 2020, The New England journal of medicine.
[3] C. Di Mario,et al. Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems. , 2020, The Canadian journal of cardiology.
[4] J. Moon,et al. Cardiac amyloidosis in aortic stenosis: The tip of the iceberg. , 2018, The Journal of thoracic and cardiovascular surgery.
[5] George H Sack,et al. Serum amyloid A – a review , 2018, Molecular Medicine.
[6] A. Petrie,et al. A new staging system for cardiac transthyretin amyloidosis , 2018, European heart journal.
[7] M. Leon,et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement , 2017, European heart journal.
[8] C. Rapezzi,et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths , 2017, European heart journal.
[9] Giampaolo Merlini,et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines , 2016, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[10] James C Moon,et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.
[11] E. González-López,et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.
[12] A. Foli,et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. , 2015, Blood.
[13] A. Cheung,et al. Pathology of transcatheter valve therapy. , 2012, JACC. Cardiovascular interventions.
[14] C. Selmi,et al. Currents Concepts on the Immunopathology of Amyloidosis , 2010, Clinical reviews in allergy & immunology.
[15] F. Salvi,et al. Usefulness of 99mTc-DPD scintigraphy in cardiac amyloidosis. , 2008, Journal of the American College of Cardiology.
[16] A. Singleton,et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2‐macroglobulin and tau: A population‐based autopsy study , 2008, Annals of medicine.
[17] P. Hawkins,et al. Systemic amyloidosis. , 2006, Current opinion in pharmacology.
[18] F. Salvi,et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. , 2005, Journal of the American College of Cardiology.
[19] R A Kyle,et al. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. , 1983, The American journal of medicine.